Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib induction study in moderately to severely active ulcerative colitis
NL-OMON49361Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Upadacitinib 45 mg once daily with Placebo once daily (2 arms). Primary endpoint: Clinical remission per Adapted Mayo score at Week 8. Planned start Oct 2018; status: withdrawn.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON49361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49361.